Navigation Links
Sangamo BioSciences Proposes Public Offering Of Common Stock
Date:9/17/2013

iper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis MN 55402, or via telephone at 800-747-3924.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and  hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Huntington's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and it has also established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, In
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
2. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
3. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
4. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
5. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
6. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
7. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
8. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
9. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
10. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
11. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 2013 was a banner year ... Technologies®. They saw continued independent research led by the ... awarded a $1 million grant from the Susanne Marcus ... Behavior” a peer reviewed journal, Amy Grant highlighted Brainwave ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... elected mayor of Colorados largest city, businessman John Hickenlooper invited ... was to ceremoniously bury the hatchet of intra-regional rivalry and ... metropolitan area, or not at all. , ,Every suburban ... a near-unanimous effort to pass a $4.7-billion mass transit initiative ...
... data quality firm Firstlogic for about $69 million ... second quarter. , ,Firstlogic is a privately held firm that ... sure their data is as correct as they need to ... call centers, web sites, customer relationship management systems, and business ...
... settled with a Belgian company that sued last September ... virus genotyping technology from Innogenetics, for undisclosed financial terms. ... Aril 2004 Third Wave forged a deal under which ... line of products in Europe. It was Third Wave's ...
Cached Biology Technology:Economic collaboration in Denver sets tall goal for Wisconsin 2Economic collaboration in Denver sets tall goal for Wisconsin 3
(Date:4/23/2014)... using triclosan as an antimicrobial ingredient in soaps, toothpastes ... are reporting new evidence that appears to support these ... Chemical Research in Toxicology , found that triclosan, as ... growth of human breast cancer cells in lab dishes ... and colleagues note that hormonal imbalances seem to play ...
(Date:4/23/2014)... of the family of bacteria that causes whooping ... reveals surprising findings about the bacteria,s origin and ... strategies to control this respiratory disease, which kills ... of 343 strains of the Bordetella pertussis ... the last 100 years illustrates how vaccination has ...
(Date:4/23/2014)... HOUSTON, April 23, 2014 A biomedical engineer at ... highly innovative technology to make blood transfusions safer. His ... the National Institutes of Health (NIH). , Blood ... one of modern medicine,s absolute necessities. Without them, for ... mean transfusions are perfect, however. There,s strong evidence that ...
Breaking Biology News(10 mins):In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Impact of whooping cough vaccination revealed 2UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3
... a single dose of chemotherapy alongside radiotherapy could improve ... long-term side-effects, a new study reports.,As many as 96% ... ten years from diagnosis (1), but more advanced forms ... can have serious long-term complications.,Researchers at The Institute of ...
... terrorists targeted the United States with an anthrax attack, health ... such as knowing the likelihood of an individual becoming infected, ... how long to give antibiotics to protect people from ... letters killed five people and infected 17 others in the ...
... and herbs, especially Mexican oregano, all contain apigenin and ... the lab by inhibiting an important enzyme, according to ... induced cell death in two aggressive human pancreatic cancer ... we pre-treated cancer cells with apigenin for 24 hours, ...
Cached Biology News:Chemotherapy before radiotherapy for testicular cancer could reduce long-term side-effects 2Answering crucial questions about anthrax exposure 2Answering crucial questions about anthrax exposure 3Answering crucial questions about anthrax exposure 4Celery, artichokes contain flavonoids that kill human pancreatic cancer cells 2
RABBIT ANTI ISOCITRATE DEHYDROGENASE...
... two highly efficient methods of identifying recombinant ... By using the large-scale screen method in ... is to transfer partial colonies of E. ... into the solutions provided by the kits ...
Recombinant Rat Leptin, CF...
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
Biology Products: